Developing innovative tyrosine kinase inhibitors
AB Science (ab-science.com) earns a Brand Analyzer score of 57 out of 100, placing it in the Developing tier among Healthcare brands. Among 2305 Healthcare brands analyzed, AB Science ranks in the 9th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 88/100, Digital Presence 29/100, Visual Identity 92/100, Messaging Clarity 100/100, Trust Foundation 33/100, AI Discoverability 82/100, Brand Authority 28/100.
AB Science is a clinical-stage biopharmaceutical company founded in 2001 and headquartered in Paris, France. It focuses on developing targeted therapies for serious diseases with unmet medical needs. The company is currently advancing two main compounds: masitinib, a highly selective tyrosine kinase inhibitor, and AB8939. Masitinib has shown substantial survival benefits and preserved quality of life in patients with ALS (amyotrophic lateral sclerosis), which is among the primary disease areas the company addresses.
| Brand Name | AB Science |
|---|---|
| Domain | ab-science.com |
| Industry | Healthcare |
| Founded | 2001 |
| Headquarters | Paris |
| Main Competitors | Biogen (78/100), Amylyx Pharmaceuticals, Novartis (84/100), Blueprint Medicines, Deciphera Pharmaceuticals |
Moz Domain Authority 45/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #2,259,669 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "AB Science is currently developing two main compounds, masitinib, a highly selective tyrosine kinase inhibitor and AB8939." (Meta description: 17 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Instagram, YouTube; no detected presence on X (Twitter), LinkedIn, Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
AB Science's main competitors include Biogen (78/100), Amylyx Pharmaceuticals, Novartis, Blueprint Medicines, Deciphera Pharmaceuticals. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: AB Science official site
AB Science and Biogen are competitors in Healthcare. Brand Analyzer scores AB Science at 57/100 and Biogen at 78/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: AB Science official site
AB Science's product pipeline centers on two main compounds. The first is masitinib, a highly selective tyrosine kinase inhibitor being developed for serious diseases including ALS, where it has shown substantial survival benefits and preserved quality of life in patients. The second compound is AB8939, which is also in development. These are investigational drug candidates rather than commercially approved products, consistent with AB Science's positioning as a clinical-stage biopharmaceutical company.
Sources: AB Science official site
Popular alternatives to AB Science include Biogen (78/100), Amylyx Pharmaceuticals, Novartis, Blueprint Medicines, Deciphera Pharmaceuticals. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: AB Science official site
AB Science is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2001. It specializes in the research and development of targeted therapies aimed at serious diseases with unmet medical needs. The company focuses on tyrosine kinase inhibitors, a class of molecularly targeted drugs, and is currently advancing two principal compounds: masitinib and AB8939. AB Science operates within the broader healthcare and pharmaceutical sector, positioning itself as a developer of precision medicines for conditions such as ALS.
Sources: AB Science official site
AB Science was founded in 2001. AB Science operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
AB Science is headquartered in Paris. AB Science operates in the Healthcare category.
Sources: Wikidata
AB Science develops targeted pharmaceutical compounds intended to treat serious diseases. Its primary focus is on masitinib, a highly selective tyrosine kinase inhibitor, and AB8939. Masitinib is being investigated notably for the treatment of ALS (amyotrophic lateral sclerosis), where it has demonstrated substantial survival benefits and preserved quality of life in patients. The company's work is centered on advancing these compounds through clinical development to address significant unmet medical needs in conditions where effective treatments are limited.
Sources: AB Science official site
AB Science is known for developing masitinib, a highly selective tyrosine kinase inhibitor. Masitinib has gained particular attention for its application in ALS (amyotrophic lateral sclerosis), where clinical data has shown substantial survival benefits and preservation of quality of life in patients. The company is also recognized for its specialization in targeted therapies for serious diseases with unmet medical needs, and for advancing a second compound, AB8939, alongside masitinib.
Sources: AB Science official site
AB Science can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: AB Science official site
AB Science's target audience includes patients with ALS and other severe diseases who may benefit from its investigational therapies, particularly masitinib. Healthcare professionals such as neurologists and oncologists engaged in clinical research or treatment of these conditions are also part of the intended audience. Additionally, investors interested in clinical-stage biopharmaceutical development represent a key stakeholder group for the company.
Sources: AB Science official site
Ranked closest to AB Science: Zavod zdravstvenog osiguranja ZDK (58/100), Zoo Health (58/100), Accelus Inc. (57/100), AccessGPS (57/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Dassault Systèmes (95/100).